|Bid||60.10 x 900|
|Ask||75.00 x 900|
|Day's range||62.00 - 66.54|
|52-week range||10.72 - 79.75|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2021 - 05 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||83.38|
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.